Meera Agar1,2,3,4,5, Eng-Siew Koh6,7,8,9, Emma Gibbs10, Elizabeth H Barnes10, Elizabeth Hovey7,11,12, Ann Livingstone10, Kate Sawkins10, Richard Chye13, Melanie R Lovell14,15, Katherine Clark16,17, Janette Vardy14,18, Madeleine King19. 1. Discipline of Palliative and Supportive Services, Flinders University, Adelaide, Australia. meera.agar@sswahs.nsw.gov.au. 2. South West Sydney Clinical School, University of New South Wales, Sydney, Australia. meera.agar@sswahs.nsw.gov.au. 3. Department of Palliative Care, Braeside Hospital, HammondCare, Sydney, Australia. meera.agar@sswahs.nsw.gov.au. 4. Ingham Institute of Applied Medical Research, Sydney, Australia. meera.agar@sswahs.nsw.gov.au. 5. Liverpool Cancer Therapy Centre, Liverpool Hospital, Sydney, Australia. meera.agar@sswahs.nsw.gov.au. 6. Discipline of Palliative and Supportive Services, Flinders University, Adelaide, Australia. 7. South West Sydney Clinical School, University of New South Wales, Sydney, Australia. 8. Ingham Institute of Applied Medical Research, Sydney, Australia. 9. Liverpool Cancer Therapy Centre, Liverpool Hospital, Sydney, Australia. 10. National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. 11. Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia. 12. University of New South Wales, Sydney, Australia. 13. Sacred Heart Supportive and Palliative Care, St Vincent's Hospital, Sydney, Australia. 14. Sydney Medical School, University of Sydney, Sydney, Australia. 15. Department of Palliative Care, Greenwich Hospital, HammondCare, Sydney, Australia. 16. Department of Palliative Care, Calvary Mater Hospital, Newcastle, Australia. 17. School of Medicine and Public Health, University of Newcastle, Callaghan, Australia. 18. Concord Cancer Centre, Concord Hospital, Sydney, Australia. 19. Psycho-oncology Co-operative Research Group (PoCoG), School of Psychology, University of Sydney, Sydney, Australia.
Abstract
PURPOSE: In brain tumours, brain metastases or advanced cancer; treatment with corticosteroids, side effects can add to symptoms. These are best assessed by patients, complementing clinical assessment. We assessed the feasibility and validity of the Dexamethasone Symptom Questionnaire-Chronic (DSQ-Chronic), patient and caregiver versions. METHODS: A longitudinal cohort study was conducted, collecting clinician-rated toxicity, performance status, dexamethasone dose and DSQ-Chronic (patient and caregiver versions) at baseline, then 2, 4 and 8 weeks later. Patients had a primary malignant brain tumour, brain metastases, or advanced cancer; Karnofsky Performance Status ≥40 and predicted survival ≥8 weeks. Analysis included questionnaire completion rates, frequency and severity of dexamethasone-attributable side effects, agreement between patient and caregiver ratings, comparison with clinician-rated toxicity and correlation with performance status. RESULTS: Sixty-six patients were recruited (mean age 60 years), with their caregivers. Completion of questionnaires was over 90% for the dyad at baseline but dropped over time, with caregiver completion rates higher at all timepoints. Agreement between patients and proxies was fair to moderate, and while proxies systematically overestimated symptom severity on DSQ-chronic total scores, the bias was less than 10 points. Patient and clinician agreement was higher for more objective symptoms. CONCLUSION: The DSQ-Chronic is feasible when the patient is relatively well. As capacity to complete the DSQ-Chronic diminishes, caregivers can be proxy-raters. Clinicians capture corticosteroid toxicities, which may not be obvious to the patient. The DSQ-Chronic, patient and caregiver versions, are useful tools to be used with clinician assessment.
PURPOSE: In brain tumours, brain metastases or advanced cancer; treatment with corticosteroids, side effects can add to symptoms. These are best assessed by patients, complementing clinical assessment. We assessed the feasibility and validity of the Dexamethasone Symptom Questionnaire-Chronic (DSQ-Chronic), patient and caregiver versions. METHODS: A longitudinal cohort study was conducted, collecting clinician-rated toxicity, performance status, dexamethasone dose and DSQ-Chronic (patient and caregiver versions) at baseline, then 2, 4 and 8 weeks later. Patients had a primary malignant brain tumour, brain metastases, or advanced cancer; Karnofsky Performance Status ≥40 and predicted survival ≥8 weeks. Analysis included questionnaire completion rates, frequency and severity of dexamethasone-attributable side effects, agreement between patient and caregiver ratings, comparison with clinician-rated toxicity and correlation with performance status. RESULTS: Sixty-six patients were recruited (mean age 60 years), with their caregivers. Completion of questionnaires was over 90% for the dyad at baseline but dropped over time, with caregiver completion rates higher at all timepoints. Agreement between patients and proxies was fair to moderate, and while proxies systematically overestimated symptom severity on DSQ-chronic total scores, the bias was less than 10 points. Patient and clinician agreement was higher for more objective symptoms. CONCLUSION: The DSQ-Chronic is feasible when the patient is relatively well. As capacity to complete the DSQ-Chronic diminishes, caregivers can be proxy-raters. Clinicians capture corticosteroid toxicities, which may not be obvious to the patient. The DSQ-Chronic, patient and caregiver versions, are useful tools to be used with clinician assessment.
Authors: Eefje M Sizoo; Linda Dirven; Jaap C Reijneveld; Tjeerd J Postma; Jan J Heimans; Luc Deliens; H Roeline W Pasman; Martin J B Taphoorn Journal: J Neurooncol Date: 2013-10-29 Impact factor: 4.130
Authors: D Steinmann; D Vordermark; H Geinitz; R Aschoff; A Bayerl; J Gerstein; M Hipp; B van Oorschot; H J Wypior; C Schäfer Journal: Strahlenther Onkol Date: 2012-11-18 Impact factor: 3.621
Authors: Jennifer M Jones; Christine J McPherson; Camilla Zimmermann; Gary Rodin; Lisa W Le; S Robin Cohen Journal: J Pain Symptom Manage Date: 2011-03-31 Impact factor: 3.612
Authors: Megan Doyle; Nicole Marie Eve Bradley; Kathy Li; Emily Sinclair; Kelvin Lam; Grace Chan; Edward Chow; Elizabeth A Barnes; Cyril Danjoux; May N Tsao Journal: J Palliat Med Date: 2007-04 Impact factor: 2.947
Authors: Ornulf Paulsen; Pål Klepstad; Jan Henrik Rosland; Nina Aass; Eva Albert; Peter Fayers; Stein Kaasa Journal: J Clin Oncol Date: 2014-07-07 Impact factor: 44.544
Authors: Nils D Arvold; Terri S Armstrong; Katherine E Warren; Susan M Chang; Lisa M DeAngelis; Jaishri Blakeley; Marc C Chamberlain; Erin Dunbar; Herbert H Loong; David R Macdonald; David A Reardon; Michael A Vogelbaum; Ying Yuan; Michael Weller; Martin van den Bent; Patrick Y Wen Journal: Neuro Oncol Date: 2018-06-18 Impact factor: 12.300
Authors: Christopher Brzozek; Kurt K Benke; Berihun M Zeleke; Michael J Abramson; Geza Benke Journal: Int J Environ Res Public Health Date: 2018-03-26 Impact factor: 3.390